Cytoreductive surgery is a procedure aimed at removing as much of a tumor as possible, particularly in cases of advanced cancer that has spread within the abdominal cavity. When combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), this approach offers a targeted treatment modality that can enhance the effectiveness of chemotherapy. HIPEC involves delivering heated chemotherapy directly to the abdominal cavity during surgery, allowing for higher concentrations of the drug to be applied locally, minimizing systemic side effects and potentially improving outcomes for patients with certain types of cancers, such as ovarian and peritoneal carcinomatosis. While cytoreductive surgery and HIPEC can offer significant benefits, it is crucial to understand the associated risks and complications, as with any major surgical procedure. These can include infection, bleeding, and complications related to anesthesia. Comprehensive preoperative evaluations and discussions with an experienced surgical team are essential to assess the individual’s candidacy for this treatment approach. As research continues to evolve, ongoing studies aim to refine techniques and improve patient selection, enhancing the overall safety and efficacy of this innovative treatment strategy.